{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T02:54:23Z","timestamp":1785034463341,"version":"3.55.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2016,3,4]],"date-time":"2016-03-04T00:00:00Z","timestamp":1457049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"DOI":"10.1371\/journal.pntd.0004506","type":"journal-article","created":{"date-parts":[[2016,3,4]],"date-time":"2016-03-04T13:36:09Z","timestamp":1457098569000},"page":"e0004506","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3\u03b2"],"prefix":"10.1371","volume":"10","author":[{"given":"Zachary T.","family":"Swinney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad A.","family":"Haubrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangluo","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakk","family":"Ramesha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Guyett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojo","family":"Mensa-Wilmot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Swinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,3,4]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra064142","article-title":"Control of neglected tropical diseases","volume":"357","author":"P.J. Hotez","year":"2007","journal-title":"N Engl J Med"},{"key":"ref2"},{"issue":"22","key":"ref3","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1021\/cr500365f","article-title":"Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis","volume":"114","author":"A.S. Nagle","year":"2014","journal-title":"Chem Rev"},{"key":"ref4"},{"issue":"9","key":"ref5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrd1500","article-title":"<italic>Biochemical mechanisms of drug action<\/italic>: <italic>what does it take for success<\/italic>?","volume":"3","author":"D.C. Swinney","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"<italic>How were new medicines discovered<\/italic>?","volume":"10","author":"D.C. Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/clpt.2012.236","article-title":"<italic>Phenotypic vs<\/italic>. <italic>target-based drug discovery for first-in-class medicines<\/italic>","volume":"93","author":"D.C. Swinney","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"ref8","first-page":"445","article-title":"Chemotherapeutics: scientific principles, methods, and results","volume":"182","author":"Ehrlich","year":"1913","journal-title":"Lancet"},{"issue":"1","key":"ref9","first-page":"31","article-title":"The role of binding kinetics in therapeutically useful drug action","volume":"12","author":"D.C. Swinney","year":"2009","journal-title":"Curr Opin Drug Discov Devel"},{"key":"ref10","first-page":"12","article-title":"<italic>Drug discoveries and molecular mechanism of action<\/italic>, in <italic>Successful Drug Discovery<\/italic>","author":"D.C. Swinney","year":"2015"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrd2082","article-title":"Drug-target residence time and its implications for lead optimization","volume":"5","author":"R.A. Copeland","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cbpa.2010.06.176","article-title":"<italic>Drug-target residence time<\/italic>: <italic>critical information for lead optimization<\/italic>","volume":"14","author":"H. Lu","year":"2010","journal-title":"Curr Opin Chem Biol"},{"issue":"19","key":"ref13","doi-asserted-by":"crossref","first-page":"12393","DOI":"10.1074\/jbc.272.19.12393","article-title":"Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid","volume":"272","author":"D.C. Swinney","year":"1997","journal-title":"J Biol Chem"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1074\/jbc.271.7.3548","article-title":"The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen","volume":"271","author":"O.H. Callan","year":"1996","journal-title":"J Biol Chem"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.amjcard.2006.04.012","article-title":"Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin","volume":"98","author":"A.A. Bartolucci","year":"2006","journal-title":"Am J Cardiol"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI108132","article-title":"<italic>The mechanism of the effect of aspirin on human platelets<\/italic>. <italic>I<\/italic>. <italic>Acetylation of a particulate fraction protein<\/italic>","volume":"56","author":"G.J. Roth","year":"1975","journal-title":"J Clin Invest"},{"key":"ref17","first-page":"313","article-title":"<italic>Thermodynamics and Binding Kinetics in Drug Discovery<\/italic>, in <italic>Thermodynamics and Kinetics of Drug Binding<\/italic>","author":"G.M. Keseru","year":"2015"},{"issue":"5911","key":"ref18","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/302790a0","article-title":"<italic>Mechanism of calcium channel blockade by verapamil<\/italic>, <italic>D600<\/italic>, <italic>diltiazem and nitrendipine in single dialysed heart cells<\/italic>","volume":"302","author":"K.S. Lee","year":"1983","journal-title":"Nature"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.mce.2008.06.006","article-title":"<italic>Sartan-AT1 receptor interactions<\/italic>: <italic>in vitro evidence for insurmountable antagonism and inverse agonism<\/italic>","volume":"302","author":"I. Van Liefde","year":"2009","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"ref20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.tips.2006.05.001","article-title":"Slow antagonist dissociation and long-lasting in vivo receptor protection","volume":"27","author":"G. Vauquelin","year":"2006","journal-title":"Trends Pharmacol Sci"},{"issue":"11\u201312","key":"ref21","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/0006-2952(75)90055-6","article-title":"On the mechanism of action of antibiotics which act as irreversible enzyme inhibitors","volume":"24","author":"R.R. Rando","year":"1975","journal-title":"Biochem Pharmacol"},{"issue":"5347","key":"ref22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1126\/science.279.5347.98","article-title":"Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis","volume":"279","author":"D.A. Rozwarski","year":"1998","journal-title":"Science"},{"issue":"24","key":"ref23","doi-asserted-by":"crossref","first-page":"13881","DOI":"10.1073\/pnas.2235848100","article-title":"<italic>The isoniazid-NAD adduct is a slow<\/italic>, <italic>tight-binding inhibitor of InhA<\/italic>, <italic>the Mycobacterium tuberculosis enoyl reductase<\/italic>: <italic>adduct affinity and drug resistance<\/italic>","volume":"100","author":"R. Rawat","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6224","key":"ref24","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1126\/science.aaa1823","article-title":"<italic>Kinase dynamics<\/italic>. <italic>Using ancient protein kinases to unravel a modern cancer drug&apos;s mechanism<\/italic>","volume":"347","author":"C. Wilson","year":"2015","journal-title":"Science"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"<italic>Treatment of Alzheimer&apos;s disease with the GSK-3 inhibitor tideglusib<\/italic>: <italic>a pilot study<\/italic>","volume":"33","author":"T. del Ser","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases","volume":"148","author":"E. Beurel","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1006\/abio.1998.2832","article-title":"An assay for glycogen synthase kinase 3 (GSK-3) for use in crude cell extracts","volume":"264","author":"W.J. Ryves","year":"1998","journal-title":"Anal Biochem"},{"key":"ref28","first-page":"1","article-title":"<italic>Evaluation of enzyme inhibitors in drug discovery<\/italic>. <italic>A guide for medicinal chemists and pharmacologists<\/italic>","volume":"46","author":"R.A. Copeland","year":"2005","journal-title":"Methods Biochem Anal"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1074\/jbc.M111.306472","article-title":"Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib","volume":"287","author":"J.M. Dominguez","year":"2012","journal-title":"J Biol Chem"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1128\/AAC.00364-08","article-title":"Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy","volume":"52","author":"K.K. Ojo","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/B978-0-12-386009-5.00009-6","article-title":"Molecular Mechanism of Action (MMOA) in Drug Discovery","volume":"47","author":"D.C. Swinney","year":"2011","journal-title":"Ann Rep Med Chem"},{"issue":"14","key":"ref32","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1111\/bph.12683","article-title":"A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands","volume":"171","author":"D.C. Swinney","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/1087057112464776","article-title":"<italic>Dual-point competition association assay<\/italic>: <italic>a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics<\/italic>","volume":"18","author":"D. Guo","year":"2013","journal-title":"J Biomol Screen"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/01.hjh.0000220403.61493.18","article-title":"<italic>Long-lasting angiotensin type 1 receptor binding and protection by candesartan<\/italic>: <italic>comparison with other biphenyl-tetrazole sartans<\/italic>","volume":"24","author":"G. Vauquelin","year":"2006","journal-title":"J Hypertens Suppl"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mds.25824","article-title":"A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy","volume":"29","author":"E. Tolosa","year":"2014","journal-title":"Mov Disord"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer&apos;s disease","volume":"45","author":"S. Lovestone","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3beta inhibitor reduces Alzheimer&apos;s pathology and rescues neuronal loss in vivo","volume":"35","author":"L. Sereno","year":"2009","journal-title":"Neurobiol Dis"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pntd.0004506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T03:17:50Z","timestamp":1567653470000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0004506"}},"subtitle":[],"editor":[{"given":"Philippe","family":"B\u00fcscher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,4]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0004506","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,4]]}}}